- TG Therapeutics recently raised its 2026 revenue guidance to about US$950 million, citing strong momentum from BRIUMVI, which delivered US$227.7 million in Q2 2026 sales.
- This shift highlights how a single high-performing therapy can rapidly reshape the company’s revenue outlook and heighten investor focus on execution and durability of BRIUMVI demand.
- Next, we’ll examine how the higher 2026 revenue guidance driven by BRIUMVI’s performance may influence TG Therapeutics’ broader investment narrative.
AI is about to change healthcare. These 42 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
TG Therapeutics Investment Narrative Recap
To own TG Therapeutics today, you need to believe BRIUMVI can sustain its current commercial traction while the company broadens its MS franchise and pipeline. The raised 2026 revenue guidance to about US$950 million reinforces that BRIUMVI execution remains the central near term catalyst, but it also magnifies the key risk: dependence on a single therapy in a fiercely competitive, evolving MS treatment market.
Among recent updates, the positive data and ongoing Phase 3 work on subcutaneous BRIUMVI stand out as most relevant. If successful, the subcutaneous formulation could materially expand BRIUMVI’s reach into the large segment of MS patients and payers preferring self-administered options, which ties directly into how durable the current revenue guidance and BRIUMVI driven story can be over the next few years.
Yet behind the headline guidance raise, investors should also be aware of rising payer scrutiny and shifting MS treatment preferences that could eventually weigh on BRIUMVI’s...
Read the full narrative on TG Therapeutics (it's free!)
TG Therapeutics' narrative projects $1.7 billion revenue and $616.2 million earnings by 2029.
Uncover how TG Therapeutics' forecasts yield a $51.71 fair value, a 6% downside to its current price.
Exploring Other Perspectives
Some of the lowest estimate analysts were already cautious, projecting about US$1.7 billion in 2029 revenue and shrinking margins, which contrasts sharply with the current BRIUMVI momentum and shows how widely views can differ before this new guidance is fully reflected.
Explore 6 other fair value estimates on TG Therapeutics - why the stock might be worth 48% less than the current price!
Form Your Own Verdict
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
- A great starting point for your TG Therapeutics research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.
- Our free TG Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate TG Therapeutics' overall financial health at a glance.
Interested In Other Possibilities?
The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:
- Capitalize on the AI infrastructure supercycle with our selection of the 55 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
- Outshine the giants: these 18 early-stage AI stocks could fund your retirement.
- Explore 24 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com